Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET)
2025-522506-20-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of flumazenil in major depressive episode (MDE), recurrent depressive disorder (RDD) and bipolar disorder (BD) (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Objective cognitive function. Planned start Sep 2025; status: authorised.
02
Drugs
flumazenil
03
Conditions
major depressive episode (MDE)recurrent depressive disorder (RDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2025-522506-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522506-20-00.